Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Apr 15;11(2):29.
doi: 10.3390/antib11020029.

Special Issue "Antibody Engineering for Cancer Immunotherapy"

Silvia Crescioli  1 , Ann L White  2 , Sophia N Karagiannis  1   3
Affiliations
Editorial

Special Issue "Antibody Engineering for Cancer Immunotherapy"

Silvia Crescioli et al. Antibodies (Basel). .

Abstract

Since the approval of Rituximab in the late 1990s, the first chimeric monoclonal antibody for the treatment of non-Hodgkin lymphoma, antibody engineering for cancer immunotherapy has become a rapidly growing field, with almost 50 antibody therapeutics approved in the USA and EU and hundreds undergoing testing in clinical trials [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Zahavi D., Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies. 2020;9:34. doi: 10.3390/antib9030034. - DOI - PMC - PubMed
    1. Charrin S., Palmulli R., Billard M., Clay D., Boucheix C., Van Niel G., Rubinstein E. Rapid Isolation of Rare Isotype-Switched Hybridoma Variants: Application to the Generation of IgG2a and IgG2b MAb to CD63, a Late Endosome and Exosome Marker. Antibodies. 2020;9:29. doi: 10.3390/antib9030029. - DOI - PMC - PubMed
    1. Li S., McCraw A.J., Gardner R.A., Spencer D.I.R., Karagiannis S.N., Wagner G.K. Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors. Antibodies. 2021;10:44. doi: 10.3390/antib10040044. - DOI - PMC - PubMed
    1. Liu R., Oldham R.J., Teal E., Beers S.A., Cragg M.S. Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment. Antibodies. 2020;9:64. doi: 10.3390/antib9040064. - DOI - PMC - PubMed
    1. van Tetering G., Evers M., Chan C., Stip M., Leusen J. Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents. Antibodies. 2020;9:70. doi: 10.3390/antib9040070. - DOI - PMC - PubMed

Publication types

LinkOut - more resources